Magdalena Kegel,  —

Initial data from a Phase 1 study of bluebird bio’s second-generation CAR T-cell therapy bb2121 for relapsed or refractory multiple myeloma showed impressive results, with all patients in the high-dose group responding to the treatment despite being a notoriously difficult-to-treat patient group. The therapy also was seen to be…

A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of myeloma cells called B-cell maturation antigen (BCMA). Researchers were able to demonstrate that P-BCMA-101…

Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two factors that drive disease in patients with relapsed or refractory multiple myeloma. Researchers believe that having two targets might be more efficient in fighting the…

Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at the Annual Meeting of the Society of Hematologic Oncology (SOHO) in Houston, Texas. The presentation was based on data from an ongoing Phase 2…

Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the field of gene-edited cancer cell therapies. The preclinical data, presented at the CAR-TCR Summit on T Cell Immunotherapies in Boston, and summarized in a…

Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is having a relapse, according to researchers from the Medical College of Georgia at Augusta University. The tests under scrutiny are three types of analyses…

The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with immunomodulatory drugs as a treatment for multiple myeloma. Myeloma patients’ deaths in trials of Keytruda (pembrolizumab)-based combinations prompted the FDA crackdown on studies of immune…

The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer therapy for multiple myeloma. The agency also placed a partial hold on five additional trials testing similar Imfinzi combinations in myeloma and other blood cancers.

Patients with relapsed or treatment-resistant multiple myeloma, who have undergone several earlier treatment rounds, have a much poorer response to combination treatments including Darzalex (daratumumab) than what has been reported in clinical trials, according to an analysis by the Mayo Clinic. Nevertheless, the research team underscored that Darzalex-containing combination…

BioLineRx is seeking regulatory approval to advance into a Phase 3 clinical trial its treatment BL-8040, for blood stem cell mobilization to prepare for autologous transplants in patients with multiple myeloma. The company hopes that the trial, called GENESIS, will allow BL-8040 to become an approved treatment for myeloma. The…